CureVac, chasing Moderna's mRNA flu vaccine, runs into the same B strain problems

CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now, the European partners have come up against the exact same problem as their U.S. competitor when it comes to the "historically challenging" B strains of influenza.